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Conclusions: Varenicline in combination with nicotine replacement
therapy is more effective than varenicline alone at achieving tobacco absti-
nence at 12 weeks and at 6 months.
Summary: The principle mediator of nicotine dependence is believed to
be the nicotinic cholinergic receptor, speciﬁcally thea4b2 receptor subtype. Var-
enicline targets this receptor with a higher afﬁnity than nicotine, blocking nico-
tine effects but also acting as a partial agonist. As such, acting as a partial agonist,
vareniclinemay intheoryblock thedirectagonist effectofnicotine (RigottiNAet
al, JAMA2012;308:1573-80).Thepurposeof this trialwas therefore to evaluate
the efﬁcacy and safety of combining varenicline and a nicotine patch vs vareni-
cline alone in smoking cessation. This was a randomized, blinded, placebo-
controlled clinical trial with a 12-week treatment period and a further 12-week
follow-up period conducted in 7 centers in South Africa from April 2011 to
October 2012. 446 generally healthy smokers were randomized (1:1); 435
were included in the efﬁcacy and safety analyses.Nicotine or placebo patch treat-
mentbegan2weeksbefore target quitdate andcontinued for a further12weeks.
Varenicline was begun 1 week prior to target quit date, continued for a further
12 weeks, and tapered off during week 13. Tobacco abstinence was established
and conﬁrmed by exhaled carbon monoxide measurements at target quit date
and at intervals thereafter up to 24 weeks. The primary end point was the
4-week exhaled carbon monoxide conﬁrmed continuous abstinence rate for
weeks 9 through 12of treatment, ie, the proportion of participants able tomain-
tain complete abstinence from smoking for the last 4 weeks of treatment, as
assessed using multiple imputation analysis. Clinical end points included point
prevalence abstinence at 6 months, continuous abstinence rate from weeks 9
through 24 weeks, and adverse events. Multiple imputation was also used to
address loss to follow-up. The combination treatment was associated with a
higher continuous abstinence rate at 12 weeks (55.4% vs 40.9%; odds ratio
[OR], 1.85; 95% conﬁdence interval [CI], 1.19-2.89; P ¼ .007) and 24 weeks
(49.0% vs 32.6%;OR, 1.98; 95%CI, 1.25-3.14; P¼ .004) and point prevalence
abstinence rate at 6 months (65.1% vs 46.7%; OR, 2.13; 95% CI, 1.32-3.43;
P¼ .002). The combination treatment group had a greater incidence of nausea,
sleep disturbance, skin reactions, constipation, and depression with only skin
reactions reaching statistical signiﬁcance (14.4% vs 7.8%; P ¼ .03). The vareni-
cline-alone group experienced more abnormal dreams and headaches.
Comment: The authors found that the combination of treatment using
nicotine replacement therapy and varenicline is more effective than vareni-
cline alone in promoting smoking cessation. The additive efﬁcacy of
combining the two drugs is not easily explained given that both target a4b2
nicotine receptors. One possibility is that neither drug fully saturates all
a4b2 nicotine receptors in the brain, allowing for action of the other. It is
also possible the drugs have different pharmacokinetics and therefore provide
more favorable onsets of receptor agonism in combination than alone. Onset
of action of nicotine release from nicotine replacement therapy is slower than
that of nicotine from smoking or that of varenicline. The study was limited to
relatively healthy smokers and this aspect as well as the speciﬁc timing of initi-
ation of both interventions and the tapering of varenicline may differ from
every day practice and limit the generalizability of the current ﬁndings. Never-
theless, it does appear that the combination of nicotine replacement therapy
and varenicline can result in clinically meaningful rates of quitting smoking
and a continued abstinence from smoking at least in the short term.Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular
Disease
Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. N Engl J Med
2014;371:32-41.
Conclusions: Loss-of-function mutations in APOC3 are associated
with low levels of triglycerides and a reduced risk of ischemic cardiovascular
disease.
Summary: Genetic studies have suggested that high levels of non-
fasting triglycerides can be causally associated with an increased risk of
ischemic cardiovascular disease, and that this is independent of high-den-
sity lipoprotein (HDL) cholesterol levels (Jørgensen AB et al, Eur Heart
J 2013;34:1826-33). Plasma triglycerides are markers of so-called remnant
particles. These include very-low-density lipoproteins, intermediate-density
lipoproteins, and chylo-micron remnants from the nonfasting state. Apoli-
poprotein C3 is a component of remnant particles that is associated with
high levels of triglycerides and thus remnant cholesterol. Apolipoprotein
C3 increases plasma triglyceride levels. A loss-of-function mutation in
the gene encoding apolipoprotein C3 (APOC3) has been associated with
signiﬁcantly reduced levels of triglycerides and remnant cholesterol and
with a decrease in coronary-artery calciﬁcation, a widely employed surro-
gate marker for atherosclerosis (Chapman MJ, Eur Heart J
2011;32:1345-61). It is unknown however, whether lifelong low levels
of nonfasting triglycerides owing to mutations in the gene encoding apoli-
poprotein C3 are associated with a reduced risk of ischemic cardiovascular
disease in the general population. To address this question the authors uti-
lized data from 75,725 participants in two general-population studies.
They ﬁrst tested whether low levels of nonfasting triglycerides were associ-
ated with reduced risks of ischemic vascular disease and ischemic heart dis-
ease. Next, they tested whether loss-of-function mutations in APOC3,
which were associated with reduced levels of nonfasting triglycerides
were also associated with reduced risks of ischemic vascular disease and
ischemic heart disease. During follow-up, ischemic vascular disease devel-
oped in 10,797 participants and ischemic heart disease developed in
7557 of these 75,725 participants. Subjects with nonfasting triglyceride
levels of <1.00 mmol per liter (90 mg per deciliter) had a signiﬁcantly
lower incidence of cardiovascular disease than those with levels of
4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio [HR]
for ischemic vascular disease, 0.43; 95% CI, 0.35-0.54; HR for ischemic
heart disease 0.40; 95% CI, 0.31-0.52). Heterozygosity for loss-of-func-
tion mutations in APOC3, as compared with no APOC3 mutations, was
associated with a mean reduction in nonfasting triglyceride levels of 44%
(P < .001). The cumulative incidences of ischemic vascular disease and
ischemic heart disease were reduced in heterozygotes as compared with
noncarriers of APOC3 mutations (P ¼ .009 and P ¼ .05, respectively),
with corresponding risk reductions of 41% (HR, 0.59; 95% CI, 0.41-
0.86; P ¼ .007) and 36% (HR, 0.64; 95% CI, 0.41-0.99; P ¼ .04).
Comment: The data indicate potentially, inhibition of APOC3 by
antisense oligonucleotides could reduce plasma levels of apolipoprotien
C3 and triglycerides. This has also been shown in animal models and in a
phase 1 clinical trial involving humans (Graham MJ, et al. Circ Res
2013;112:1479-90). The ﬁnding that loss-of-function mutations in
APOC3 is associated with reduced risk of ischemic vascular disease and
ischemic heart disease is highly relevant in that APOC3 therefore is a rele-
vant drug target for reducing cardiovascular risk.
